Abstract

BackgroundAgonistic autoantibodies against the angiotensin II receptor type 1 (AT1R) and the endothelin receptor type A (ETAR) have been identified in patients suffering from systemic sclerosis (SSc).ObjectivesHere we examined the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0517 Possible Role for Autoantibody-Mediated Activation of Immume Cells Mediated through the Angiotensin II Receptor Type 1 and the Endothelin Receptor Type A in the Pathogenesis of Systemic Sclerosis
M Radic ... E Siegert
Annals of the Rheumatic Diseases | VOL. 73
M Radic, et. al.M Radic ... E Siegert
01 Jun 2014
Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients
Gerd-Rüdiger Burmester ... Gabriela Riemekasten
Arthritis Research & Therapy | VOL. 16
Gerd-Rüdiger Burmester, et. al.Gerd-Rüdiger Burmester ... Gabriela Riemekasten
01 Jan 2014
A10.27 Systemic Sclerosis – Role of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A on Immune Cells in Disease Pathogenesis
J Günther ... G Riemekasten
Annals of the Rheumatic Diseases | VOL. 72
J Günther, et. al.J Günther ... G Riemekasten
25 Feb 2013
SAT0028 Systemic sclerosis – effects of agonistic auto-antibodies directed against the angiotensin receptor type 1 and the endothelin receptor type a on immune cells
G Riemekasten ... A Kill
Annals of the Rheumatic Diseases | VOL. 71
G Riemekasten, et. al.G Riemekasten ... A Kill
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers